Kucukcelebi, S., Land, F. R. V. â., Burg, S. H. V. D., Eskens, F. A. L. M., Homs, M. Y. V., Willemsen, M., Schoonhoven, A. O., Rozendaal, N. E. M., Fellah, A., Vadgama, D., Moskie, M., Bezemer, K., Doukas, M., Eijck, C. W. F. V., Stadhouders, R., Vos-Geelen, J. D., Diepen, A. E. V., Enninga, I., Meijer, R., Ambarkhane, S. V., Ellmark, P., Aerts, J. G. J. V., Groeneveldt, C., Eijck, C. H. J. V. (2025). REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Nature Communications. https://doi.org/10.1038/s41467-025-66092-1